1-20 of 162
Cyrille Hulin
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

Real-World Multicenter Data of Venetoclax Use in Multiple Myeloma with t(11-14). Time to Consider It Again

Jules Higué, Gaetan Basile, Titouan Cazaubiel, Anne Banos, Guillaume Beziat, Martin Gauthier, Miguel Carreiro, Noemie Gadaud, Benjamin Hebraud, Miguel Granell, Pierre Bories, Christian Récher, Jill Corre, Cyrille Hulin, Aurore Perrot, Leopoldine Lapierre, Pierre Luc Mouchel
Journal: Blood
Blood (2024) 144 (Supplement 1): 7030.
https://doi.org/10.1182/blood-2024-206954
Published: 2024
Journal Articles

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide and Dexamethasone (VRd) Versus Alone in Patients with Transplant-Ineligible Newly Diagnosed Multiple Myeloma or for Whom Transplant Is Not Planned As Initial Therapy: Analysis of Minimal Residual Disease in the Cepheus Trial

Sonja Zweegman, Thierry Facon, Vania Hungria, Nizar J. Bahlis, Christopher P. Venner, Marc Braunstein, Luděk Pour, Josep Marti Tutusaus, Supratik Basu, Yael C. Cohen, Morio Matsumoto, Kenshi Suzuki, Cyrille Hulin, Sebastian Grosicki, Wojciech Maciej Legiec, Meral Beksac, Angelo Maiolino, Hiroyuki Takamatsu, Aurore Perrot, Mehmet Turgut, Weiping Liu, Jianping Wang, Katherine Chastain, Jessica Vermeulen, Maria Krevvata, Lorena Lopez-Masi, Jodi Carey, Melissa Rowe, Robin Carson, Saad Z. Usmani
Journal: Blood
Blood (2024) 144 (Supplement 1): 362.
https://doi.org/10.1182/blood-2024-200871
Published: 2024
Journal Articles

Health-Related Quality of Life in Transplant-Eligible Patients with Newly Diagnosed Multiple Myeloma: Data from the Perseus Trial of Subcutaneous Daratumumab Combined with Bortezomib, Lenalidomide, and Dexamethasone (D-VRd)

Pieter Sonneveld, Meletios A. Dimopoulos, Mario Boccadoro, Hang Quach, Phoebe Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W.C.J. van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda Balari, Laura Rosiñol Dachs, Michel Delforge, Wilfried Roeloffzen, Christoph Driessen, Annette Vangsted, Hermann Einsele, Andrew Spencer, Roman Hajek, Artur Jurczyszyn, Sarah Lonergan, Yanfang Liu, Jianping Wang, Emilie M.J. van Brummelen, Veronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Eva G. Katz, Katharine S. Gries, Jiaqi Song, Kai Fai Ho, Paula Rodríguez-Otero, Joan Bladé, Philippe Moreau
Journal: Blood
Blood (2024) 144 (Supplement 1): 2000.
https://doi.org/10.1182/blood-2024-201630
Published: 2024
Journal Articles

Pharmacodynamic Profiles of Patients (Pts) with Newly Diagnosed (ND) Vs Relapsed/Refractory Multiple Myeloma (RRMM) Who Received Teclistamab (Tec) or Talquetamab (Tal) Plus Daratumumab (Dara) and Lenalidomide (Len) in the Phase 1b Majestec-2 and Monumental-2 Studies

Diana Cortes, Brendan Paul Hodkinson, Ashwini Kumar, Sheri Skerget, Gary E Mason, Elizabeth Shearin, Hein Ludlage, Bas D Koster, Colleen Kane, Thomas Renaud, Tobias Kampfenkel, Christoph Heuck, Bhoomika Thakkar, Farheen Zishan, Emma Searle, Hang Quach, Gayathri Ravi, Cyrille Hulin, Wojciech Janowski, Jesus G Berdeja, Sébastien Anguille, Jeffrey V Matous, Cyrille Touzeau, Anne-Sophie Michallet, Ajay K. Nooka, Tara Cochrane, Anita D'Souza, Peter M. Voorhees, Karthik Ramasamy, Aurore Perrot, Andrew Spencer, Gurdeep Parmar, Deeksha Vishwamitra
Journal: Blood
Blood (2024) 144 (Supplement 1): 4653.
https://doi.org/10.1182/blood-2024-200333
Published: 2024
Journal Articles

High-Risk Multiple Myeloma in Benefit (IFM 2020-05) Phase 3 Randomized Study of Isatuximab (Isa) Plus Lenalidomide and Dexamethasone (Rd) with Bortezomib Versus Isard in Patients with Newly Diagnosed Transplant Ineligible Multiple Myeloma (NDMM TI)

Jill Corre, Jérôme Lambert, Arthur Bobin, Salomon Manier, Aurore Perrot, Lionel Karlin, Murielle Roussel, Noemie Bigot, Omar Benbrahim, Olivier Thierry Allangba, Philippe Rey, Veronique Dorvaux, Marguerite Vignon, Virginie Roland, Reda Garidi, Jean-Noel Bastie, Marie-Lorraine Chrétien, Sophie Godet, Lydia Montes, Brieuc Cherel, Thomas Chalopin, Borhane Slama, Kamel Laribi, Claire Dingremont, Christophe Roul, Valentine Richez, Clara Mariette, Sophie Rigaudeau, Claire Calmettes, Mamoun Dib, Mourad Tiab, Laure Vincent, Jacques Delaunay, Jean Pierre Marolleau, Pascal Godmer, Laurent Frenzel, Ronan Le Calloch, Emilie Chalayer, Helene Gardeney, Margaret Macro, Bruno Royer, Olivier Decaux, Bertrand Arnulf, Karim Belhadj Merzoug, Cyrille Touzeau, Mohamad Mohty, Aurelie Gontier, Amine Kasmi, Philippe Moreau, Thierry Facon, Herve Avet Loiseau, Cyrille Hulin, Xavier Leleu
Journal: Blood
Blood (2024) 144 (Supplement 1): 4756.
https://doi.org/10.1182/blood-2024-210345
Published: 2024
Journal Articles

The IFM2017-03 Phase 3 Trial: A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide for Frail Patients with Newly-Diagnosed Multiple Myeloma

Salomon Manier, Jérome Lambert, Cyrille Hulin, Kamel Laribi, Carla Araujo, Gian Matteo Pica, Cyrille Touzeau, Pascal Godmer, Bohrane Slama, Lionel Karlin, Frederique Orsini Piocelle, Mamoun Dib, Magaret Macro, Laurence Sanhes, Lydia Montes, Abderrazak El Yamani, Mourad Tiab, Reza Tabrizi, Laurent Garderet, Bruno Royer, Benoit Bareau, Aurore Perrot, Jean Yves Mary, Jill Corre, Herve Avet Loiseau, Philippe Moreau, Xavier Leleu, Thierry Facon
Journal: Blood
Blood (2024) 144 (Supplement 1): 774.
https://doi.org/10.1182/blood-2024-203045
Published: 2024
Journal Articles

Talquetamab, a GPRC5D×CD3 Bispecific Antibody, in Combination with Daratumumab and Lenalidomide in Patients with Newly Diagnosed Multiple Myeloma: Safety and Efficacy Results from the Phase 1b Monumental-2 Study

Ajay K. Nooka, Tara Cochrane, Anita D'Souza, Jeffrey V Matous, Peter M. Voorhees, Karthik Ramasamy, Aurore Perrot, Andrew Spencer, Cyrille Hulin, Hang Quach, Deeksha Vishwamitra, Ashley Nguyen, Debopriya Ghosh, Elizabeth Shearin, Gary E Mason, Thomas Renaud, Gurdeep Parmar
Journal: Blood
Blood (2024) 144 (Supplement 1): 1975.
https://doi.org/10.1182/blood-2024-199773
Published: 2024
Journal Articles

Daratumumab, carfilzomib, lenalidomide, and dexamethasone with tandem transplant for high-risk newly diagnosed myeloma

Clinical Trials & Observations
Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chretien, Lionel Karlin, Martine Escoffre, Caroline Jacquet, Mourad Tiab, Xavier Leleu, Herve Avet-Loiseau, Alexandra Jobert, Lucie Planche, Jill Corre, Philippe Moreau
Journal: Blood
Blood (2024) 143 (20): 2029–2036.
https://doi.org/10.1182/blood.2023023597
Published: 2024
Includes: Supplemental data
Journal Articles

Phase 3 Randomized Study of Daratumumab (DARA) + Bortezomib, Lenalidomide, and Dexamethasone (VRd) Versus Vrd Alone in Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM) Who Are Eligible for Autologous Stem Cell Transplantation (ASCT): Primary Results of the Perseus Trial

Pieter Sonneveld, Meletios A. Dimopoulos, Mario Boccadoro, Hang Quach, P. Joy Ho, Meral Beksac, Cyrille Hulin, Elisabetta Antonioli, Xavier Leleu, Silvia Mangiacavalli, Aurore Perrot, Michele Cavo, Angelo Belotti, Annemiek Broijl, Francesca Gay, Roberto Mina, Inger S. Nijhof, Niels W.C.J van de Donk, Eirini Katodritou, Fredrik Schjesvold, Anna Sureda Balari, Laura Rosiñol, Michel Delforge, Wilfried Roeloffzen, Tobias Silzle, Annette Vangsted, Hermann Einsele, Andrew Spencer, Roman Hajek, Artur Jurczyszyn, Sarah Lonergan, Tahamtan Ahmadi, Yanfang Liu, Jianping Wang, Diego Vieyra, Emilie M.J. van Brummelen, Veronique Vanquickelberghe, Anna Sitthi-Amorn, Carla J. de Boer, Robin Carson, Paula Rodríguez Otero, Joan Bladé, Philippe Moreau
Journal: Blood
Blood (2023) 142 (Supplement 2): LBA-1.
https://doi.org/10.1182/blood-2023-191911
Published: 2023
Journal Articles

Iberdomide Maintenance after Autologous Stem-Cell Transplantation in Newly Diagnosed MM: First Results of the Phase 2 EMN26 Study

Niels W.C.J. van de Donk, Cyrille Touzeau, Evangelos Terpos, Aurore Perrot, Roberto Mina, Maaike de Ruijter, Elisabetta Antonioli, Eirini Katodritou, Norbert Pescosta, Paulus A.F. Geerts, Cécile Sonntag, Ruth Wester, Angelo Belotti, Silvia Mangiacavalli, Massimo Offidani, Mattia D'Agostino, Mark van Duin, Michele Cavo, Sara Aquino, Alessandra Lombardo, Mark-David Levin, Cyrille Hulin, Mario Boccadoro, Pieter Sonneveld, Francesca Gay
Journal: Blood
Blood (2023) 142 (Supplement 1): 208.
https://doi.org/10.1182/blood-2023-177564
Published: 2023
Journal Articles

Real-World Outcomes of Newly Diagnosed Multiple Myeloma (NDMM) Patients Treated before the Anti-CD38 Antibodies Era in France, the Emmy Cohort 2017 to 2020

Laure Vincent, Olivier Decaux, Aurore Perrot, Bruno Royer, Thomas Chalopin, Arthur Bobin, Margaret Macro, Denis Caillot, Lionel Karlin, Caroline Jacquet, Cécile Sonntag, Mohamad Mohty, Laurent Frenzel, Arnaud Jaccard, Laurence Sanhes, Driss Chaoui, Nathalie Texier, Chanaz Louni, Zakaria Maarouf, Herve Avet Loiseau, Cyrille Hulin, Karim Belhadj Merzoug
Journal: Blood
Blood (2023) 142 (Supplement 1): 3355.
https://doi.org/10.1182/blood-2023-173845
Published: 2023
Journal Articles

Dose Escalation of ISB 1342, a Novel CD38xCD3 Bispecific Antibody, in Patients with Relapsed / Refractory Multiple Myeloma (RRMM)

Prashant Kapoor, Don A. Stevens, Xavier Leleu, Karim Belhadj Merzoug, Lionel Karlin, Salomon Manier, Thomas Chalopin, Cyrille Hulin, Aurore Perrot, Jésus G Berdeja, Cristiana Costa Chase, Cyrille Touzeau, Philippe Moreau, Sanjay Mohan, Alexander Lesokhin, Carol Huff, David H. Vesole, Joshua Richter, Jeffrey Matous, Eileen Wolff, Tejas Shah, Jeppe Koch-Olsen, Andrew Garton, Vinu Menon, Sunitha Gn, Mario Perro, Eugene Zhukovsky, Cyril Konto, Lida Pacaud, Mohamad Mohty
Journal: Blood
Blood (2023) 142 (Supplement 1): 3339.
https://doi.org/10.1182/blood-2023-186664
Published: 2023
Journal Articles

Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone Induction and Consolidation with Tandem Transplant in High-Risk Newly Diagnosed Myeloma Patients: Final Results of the Phase 2 Study IFM 2018-04

Cyrille Touzeau, Aurore Perrot, Cyrille Hulin, Salomon Manier, Margaret Macro, Marie-Lorraine Chretien, Lionel Karlin, Olivier Decaux, Caroline Jacquet, Mourad Tiab, Xavier Leleu, Jill Corre, Alexandra Jobert, Lucie Planche, Herve Avet-Loiseau, Philippe Moreau
Journal: Blood
Blood (2023) 142 (Supplement 1): 207.
https://doi.org/10.1182/blood-2023-174044
Published: 2023
Journal Articles

Ixazomib, Pomalidomide and Dexamethasone (IxPd) in Relapsed or Refractory Multiple Myeloma (RRMM) Characterized with High-Risk Cytogenetics. IFM 2014-01

Arthur Bobin, Salomon Manier, Joe De Keizer, Cyrille Hulin, Lionel Karlin, Denis Caillot, Clara Mariette, Carla Araujo, Bertrand Arnulf, Benoit Bareau, Karim Belhadj Merzoug, Lotfi Benboubker, Thorsten Braun, Claire Calmettes, Olivier Decaux, Mamoun Dib, Helene Demarquette, Pierre Feugier, Cécile Sonntag, Arnaud Jaccard, Pascal Lenain, Margaret Macro, Valentine Richez, Mourad Tiab, Laure Vincent, Hacene Zerazhi, Marie-Odile Petillon, Cyrille Touzeau, Aurore Perrot, Philippe Moreau, Thierry Facon, Herve Avet Loiseau, Xavier Leleu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6724.
https://doi.org/10.1182/blood-2023-186599
Published: 2023
Journal Articles

Multicenter Open Label Phase 3 Benefit Study of Isatuximab Plus Lenalidomide and Dexamethasone with/without Bortezomib in the Treatment of Newly Diagnosed Non-Frail Transplant Ineligible Multiple Myeloma Elderly Patients. IFM2020-05

Arthur Bobin, Cyrille Hulin, Jerome Lambert, Aurore Perrot, Salomon Manier, Lydia Montes, Arnaud Jaccard, Lionel Karlin, Pascal Godmer, Denis Caillot, Thomas Chalopin, Christophe Roul, Clara Mariette, Sophie Rigaudeau, Jacques Delaunay, Claire Dingremont, Alberto Santagostino, Mamoun Dib, Margaret Macro, Mourad Tiab, Kamel Laribi, Emmanuelle Bourgeois Petit, Claire Calmettes, Frederique Orsini Piocelle, Benoit Bareau, Reza Tabrizi, Laure Vincent, Mohamad Mohty, Cyrille Touzeau, Jill Corre, Philippe Moreau, Thierry Facon, Herve Avet Loiseau, Xavier Leleu
Journal: Blood
Blood (2023) 142 (Supplement 1): 6741.
https://doi.org/10.1182/blood-2023-185699
Published: 2023
Journal Articles

Biallelic deletion of 1p32 defines ultra-high-risk myeloma, but monoallelic del(1p32) remains a strong prognostic factor

CME Clinical Trials & Observations
Anaïs Schavgoulidze, Alexis Talbot, Aurore Perrot, Titouan Cazaubiel, Xavier Leleu, Salomon Manier, Laure Buisson, Sabrina Mahéo, Laura Do Souto Ferreira, Luka Pavageau, Cyrille Hulin, Jean-Pierre Marolleau, Laurent Voillat, Karim Belhadj, Marion Divoux, Borhane Slama, Sabine Brechignac, Margaret Macro, Anne-Marie Stoppa, Laurence Sanhes, Frédérique Orsini-Piocelle, Jean Fontan, Marie-Lorraine Chretien, Hélène Demarquette, Mohamad Mohty, Hervé Avet-Loiseau, Jill Corre
Journal: Blood
Blood (2023) 141 (11): 1308–1315.
https://doi.org/10.1182/blood.2022017863
Published: 2023
Includes: Supplemental data
Journal Articles

A Dexamethasone Sparing-Regimen with Daratumumab and Lenalidomide in Frail Patients with Newly-Diagnosed Multiple Myeloma: Efficacy and Safety Analysis of the Phase 3 IFM2017-03 Trial

Salomon Manier, Jill Corre, Cyrille Hulin, Kamel Laribi, Carla Araujo, Gian-Matteo Pica, Cyrille Touzeau, Pascal Godmer, Bohrane Slama, Lionel Karlin, Frederique Orsini-Piocelle, Mamoun Dib, Margaret Macro, Laurence Sanhes, Aurore Perrot, Jean Yves Mary, Jerome Lambert, Herve Avet-Loiseau, Philippe Moreau, Xavier Leleu, Thierry Facon
Journal: Blood
Blood (2022) 140 (Supplement 1): 1369–1370.
https://doi.org/10.1182/blood-2022-159933
Published: 2022
Journal Articles

Health-Related Quality of Life for Frail Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Treated with Daratumumab, Lenalidomide and Dexamethasone: Subgroup Analysis of MAIA Trial

Aurore Perrot, Thierry Facon, Torben Plesner, Saad Usmani, Shaji K Kumar, Nizar Jacques Bahlis, Cyrille Hulin, Robert Z. Orlowski, Hareth Nahi, Peter Mollee, Karthik Ramasamy, Murielle Roussel, Arnaud Jaccard, Michel Delforge, Lionel Karlin, Bertrand Arnulf, Ajai Chari, Huiling Pei, Niodita Gupta, Shuchita Kaila, Kathryn Matt, Katharine S. Gries, Robin Carson, Fredrik Borgsten, Katja Weisel
Journal: Blood
Blood (2022) 140 (Supplement 1): 1142–1145.
https://doi.org/10.1182/blood-2022-165524
Published: 2022
Journal Articles

Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) in Transplant-Ineligible Patients (Pts) with Newly Diagnosed Multiple Myeloma (NDMM): Clinical Assessment of Key Subgroups of the Phase 3 Maia Study

Philippe Moreau, Thierry Facon, Saad Usmani, Nizar Jacques Bahlis, Noopur Raje, Torben Plesner, Robert Z. Orlowski, Supratik Basu, Hareth Nahi, Cyrille Hulin, Hang Quach, Hartmut Goldschmidt, Michael O'Dwyer, Aurore Perrot, Christopher P. Venner, Katja Weisel, Mourad Tiab, Margaret Macro, Laurent Frenzel, Xavier Leleu, Huiling Pei, Maria Krevvata, Robin Carson, Fredrik Borgsten, Shaji K Kumar
Journal: Blood
Blood (2022) 140 (Supplement 1): 7297–7300.
https://doi.org/10.1182/blood-2022-163494
Published: 2022
Journal Articles

Teclistamab in Combination with Subcutaneous Daratumumab and Lenalidomide in Patients with Multiple Myeloma: Results from One Cohort of MajesTEC-2, a Phase1b, Multicohort Study

Emma Searle, Hang Quach, Sandy W. Wong, Luciano J. Costa, Cyrille Hulin, Wojciech Janowski, Jesus Berdeja, Sébastien Anguille, Jeffrey V. Matous, Cyrille Touzeau, Anne-Sophie Michallet, Marla Husnik, Deeksha Vishwamitra, Zhuolu Niu, Julie Larsen, Lingling Chen, Jenna D. Goldberg, Rakesh Popat, Andrew Spencer
Journal: Blood
Blood (2022) 140 (Supplement 1): 394–396.
https://doi.org/10.1182/blood-2022-159711
Published: 2022